BTIG Upgrades T2 Biosystems to Buy

Sep 04, 2015

|

NEW YORK (GenomeWeb) – Investment firm BTIG upgraded shares of molecular diagnostics firm T2 Biosystems, citing the market potential for a bacteria sepsis panel the company has under development.

Analyst Karen Koski upgraded T2 to a Buy rating from Neutral, putting a $16 target price on the company's shares. During late morning trading Friday, T2 stock was trading at $11.19.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

WHO Panel Announced

The World Health Organization has announced the members of its gene-editing committee, according to NPR.

Research Reproducibility Scores

DARPA is working on developing algorithms that gauge the credibility of research findings, Wired reports.

Tests for All Diagnosed

The American Society of Breast Surgeons recommends all women diagnosed with breast cancer be offered genetic testing, the Washington Post says.

This Week in Science

In Science this week: comparison of modern, historical rabbit exomes uncovers parallel evolution after myxoma virus exposure; and more.

Main menu